(vianews) - boiron (boi.pa) is among this list of stock assets with the highest dividend rate and return on equity on the healthcare sector.
| financial asset | price | forward dividend yield | return on equity |
|---|---|---|---|
| boiron (boi.pa) | €50.30 | 2.19% | 8.13% |
| ucb (ucb.br) | €81.48 | 1.62% | 4.81% |
several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. boiron (boi.pa)
2.19% forward dividend yield and 8.13% return on equity
boiron sa manufactures and sells homeopathic medicines in france, rest of europe, north america, and internationally. the company offers non-proprietary homeopathic medicines and homeopathic specialties; and other healthcare products include medical devices, invitro diagnostics, dietary supplements, cosmetics, and phytotherapy. it also provides homeopathic specialties comprising oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; stodal and stodaline for treating coughs; arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; camilia for the treatment of teething problems for babies; sédatif pc to treat anxiety and emotional, and minor sleep disorders; coryzalia for the treatment of cold symptoms and rhinitis; homéoptic to treat eye discomfort and irritation due to various causes for adults and children; homéovox for vocal disorders; homéoplasmine for treating irritated skin and redness; varésol to treat symptoms of chickenpox; and arnicare arthritis for use in the treatment of benign trauma pain. in addition, it offers dermoplasmine, a plant based multi-use balm that repairs and protects irritated and damaged skin; covid self-tests and rapid antigenic tests; labiameo, that used to treat outbreaks of localized cold sores; and convameo to treat physical and mental asthenia. the company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. boiron sa was founded in 1932 and is headquartered in messimy, france.
earnings per share
as for profitability, boiron has a trailing twelve months eps of €2.89.
pe ratio
boiron has a trailing twelve months price to earnings ratio of 17.4. meaning, the purchaser of the share is investing €17.4 for every euro of annual earnings.
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.13%.yearly top and bottom value
boiron's stock is valued at €50.30 at 22:30 est, below its 52-week high of €53.20 and way above its 52-week low of €37.00.
moving average
boiron's worth is way higher than its 50-day moving average of €42.91 and way higher than its 200-day moving average of €43.29.volume
today's last reported volume for boiron is 1972 which is 86.28% below its average volume of 14381.
more news about boiron.
2. ucb (ucb.br)
1.62% forward dividend yield and 4.81% return on equity
ucb sa, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. the company's primary products include cimzia for inflammatory tnf mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; vimpat, keppra, and briviact for epilepsy; neupro for parkinson's disease and restless legs syndrome; nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and zyrtec and xyzal for allergies. it also offers evenity for the treatment of osteoporosis in postmenopausal women; bimzelx for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. in addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; bepranemab to treat alzheimer's disease; and ucb0599 to treat parkinson's disease. further, it engages in contract manufacturing activities. ucb sa has collaboration agreements with amgen, biogen, roche/genentech, novartis, otsuka, and doc.ai. it operates in the united states, japan, germany, rest of europe, spain, france, china, italy, the united kingdom, ireland, belgium, and internationally. the company was incorporated in 1925 and is headquartered in brussels, belgium.
earnings per share
as for profitability, ucb has a trailing twelve months eps of €2.15.
pe ratio
ucb has a trailing twelve months price to earnings ratio of 37.9. meaning, the purchaser of the share is investing €37.9 for every euro of annual earnings.
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.81%.moving average
ucb's worth is under its 50-day moving average of €81.96 and higher than its 200-day moving average of €79.45.more news about ucb.